Tufts Center for Drug Development Study Quantifies Multimillion-Dollar Benefits of Using Single-Source Pharma Drug Development and Manufacturing Model

Share This.....Share on LinkedInTweet about this on TwitterShare on FacebookShare on Google+Email this to someone

Tufts Center for Drug Development Study Quantifies Multimillion-Dollar Benefits of Using Single-Source Pharma Drug Development and Manufacturing Model

DURHAM, N.C., Oct. 24, 2017 /PRNewswire/ — A newly released modeling study conducted by The Tufts Center for the Study of Drug Development (CSDD) finds that sponsors who employ single-source outsourcing partners, versus a multivendor development and manufacturing model, experience significant financial benefits.

 (PRNewsfoto/Thermo Fisher Scientific Inc.)

The CSDD study, which compares the financial impacts of varying contract manufacturing approaches, finds that a single-source outsourcing model shortens the drug development cycle, providing sponsors with substantial financial gains from having their products reach the market sooner. Data show that faster pre-approval development times reduced cost by nearly $21 million after taxes and increased net revenues by almost $24 million, a net gain of nearly $45 million

“Drug development costs continue to rise despite ongoing efforts across the breadth of pharmaceutical and biotech companies to curtail spending,” said Joseph A. DiMasi, director of economic analysis at Tufts CSDD and principal investigator for the study. “The results of this study suggest potential financial benefits from single-source contracting.”

In addition to the economic impact for sponsors, the Tufts CSDD study concludes that a single-source partner can shorten the time needed to bring a drug to market by an average of 14 weeks. 

“Speeding up the drug development cycle not only reduces time and costs for pharmaceutical companies, it also accelerates the speed at which medicines reach the hands of doctors and patients worldwide who are waiting for these life-saving therapies,” said Michel Lagarde, senior vice president and president of pharma services, Thermo Fisher Scientific.

The Tufts CSDD study was supported by a grant from Patheon now a part of Thermo Fisher Scientific. Thermo Fisher offers a comprehensive, integrated and highly customizable set of solutions to help customers of all sizes satisfy complex development and manufacturing needs at all stages of the pharmaceutical life cycle.  For more information visit www.patheon.com

To download a white paper report of key conclusions from the study please visit: Assessing the Economics of Single-Source vs Multi-Vendor Manufacturing

About Thermo Fisher Scientific 
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of more than $20 billion and approximately 65,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive services. For more information, please visit www.thermofisher.com.

Media Contact Information:
Mari Mansfield  
Senior Director, External Communications  
001 919 632 4712

SOURCE Thermo Fisher Scientific